CureVac AG

CureVac AG

CureVac uses mRNA as an information carrier for the construction of proteins that the body can then produce itself.

Founded in 2000, the Tübingen-based biopharmaceutical company CureVac is a technology leader in the development of drugs based on messenger RNA (mRNA). The company uses the body's own principle, in which mRNA is used as an information carrier for the construction of proteins that the body can then produce itself. The RNA people pursue the major goal of bringing drugs and prophylactic vaccines based on mRNA onto the market, thereby helping patients and preventing infectious diseases.

 

RNActive® cancer immunotherapy

RNActive® cancer immunotherapies stimulate the patient's immune system to fight the tumor with a specific immune response. CureVac's compounds consist of different mRNA molecules encoding different tumor antigens (proteins or peptides that are expressed on tumor cells but show little or no expression on healthy tissues).
CureVac develops RNActive agents for the treatment of various types of cancer in collaboration with Boehringer Ingelheim and Eli Lilly.

 

RNActive® Prophylactic vaccines

RNActive® vaccines represent a new generation of promising and cost-effective mRNA-based vaccines for the prophylaxis of infectious diseases. A rabies vaccine based on a new formulation is being tested on healthy volunteers. CureVac is also working with the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines against other infectious diseases.

 

RNArt®

CureVac's mRNA-based technology RNArt® targets the body's own production of therapeutic proteins and antibodies. In rare diseases, for example, missing proteins such as enzymes can be expressed in the liver. The expression of therapeutic antibodies for the therapy of various diseases and passive immunotherapy of infections is also possible.

 

In-house GMP production

CureVac has been operating its own GMP production facilities since 2006, enabling the company to produce all (m)RNA active ingredients in a short time. The facilities have been successfully tested several times by government agencies and have received manufacturing approvals for clinical trial material. This approval was last granted in autumn 2019 for GMP III. The company is currently building another production plant in Tübingen on an industrial scale.

Category

Biotechnology

Activity Biomaterials, Biotechnology, Research, Life Science, Pharmacy

Management

Dr. Ingmar Hoerr (CEO)
Dr. Mariola Fotin-Mleczek
Dr. Franz-Werner Haas, LL.M.
Dr. Florian von der Mülbe, MBA
Pierre Kemula, B.Sc.
Dr. med. Dimitris Voliotis, MD

Year of foundation

2000

Employees

450

Supervisory board

Baron Jean Stéphenne, MSc, MBA (Vorsitzender)
Ralf Clemens, MD, PhD  
Friedrich von Bohlen und Halbach, PhD  
Mathias Hothum, PhD  
Chris Tanner, PhD  
Timothy M. Wright, MD  
Craig A. Tooman, MBA 

Academic board

Ralf Clemens, MD (Vorsitzender des wissenschaftlichen Beirats)  
Professor Nina Bhardwaj, MD  
Michel De Wilde, PhD  
Professor Dirk Jäger, MD  
Professor Karim Fizazi, MD  
Christopher Karp, MD  
Professor Michael P. Manns, MD  
Professor Stanley Plotkin, MD  
Jean-Paul Prieels, PhD  
Professor Hans-Georg Rammensee, PhD  
George R. Siber, MD  
Professor Daniel Speiser, MD  
Professor Xiao-Ning Xu, MD, PhD  
Professor Fred Zepp, MD  
Gerd Zettlmeissl, PhD

Funding

Gesamtvolumen ca. 430 Mio €

Certificates

CureVac has GMP production facilities that comply with FDA and EMEA standards.

News

02.04.2020

Jean Stéphenne Elected as New Chairman of the Supervisory Board of CureVac

CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Jean Stéphenne, former deputy Chairman of the…

15.03.2020

CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide

The company rejects current rumors of an acquisition

11.03.2020

Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG

TÜBINGEN, Germany/ BOSTON – March 11, 2020 – CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced…

03.03.2020

CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force

  • White House today invited representatives of pharmaceutical and biotech companies leading the COVID-19 response effort
  • CureVac currently selecting best vaccine…